Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases

29 Jul 2020

Abstract excerpt

Bacteria are known to evade β-lactam antibiotic action by producing β-lactamases (BLs), including carbapenemases, which are able to hydrolyze nearly all available β-lactams. The production of BLs represents one of the best known and most targeted mechanisms of resistance in bacteria. We have performed the parallel screening of commercially available compounds against a panel of clinically relevant BLs: class A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Pharmaceutical and Antibiotic Environmental Impacts
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32728062
DOI: 10.1038/s41598-020-69431-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemasesPMID 32728062Read ↗

Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase InhibitorsSemantic proximity Read ↗

β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited ResourcesSemantic proximity Read ↗

Recent advances in the development of β-lactamase inhibitorsSemantic proximity Read ↗

Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical UseSemantic proximity Read ↗

New Carbapenemase Inhibitors: Clearing the Way for the β-LactamsSemantic proximity Read ↗

Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-β-lactamasesSemantic proximity Read ↗

Progress Toward Inhibitors of Metallo-β-LactamasesSemantic proximity Read ↗

Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitorsSemantic proximity Read ↗

Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive updateSemantic proximity Read ↗

Phenotypic and in silico studies for a series of synthetic thiosemicarbazones as New Delhi metallo-beta-lactamase carbapenemase inhibitors.Semantic proximity Read ↗

Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance.Semantic proximity Read ↗

PHT427 as an effective New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor restored the susceptibility of meropenem against Enterobacteriaceae producing NDM-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.